GAUGLER DARYL
Known title: Chief Operating OfficerCIK: 0001928278
Associated companies
Transaction History
| PCRX | ▲ Buy | Grant | 244 | $4K | 12/31/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 500 | $10K | 12/13/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 500 | $6K | 9/13/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 160 | $4K | 6/28/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,000 | $28K | 6/13/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 54,300 | $0 | 6/12/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 2,754 | $85K | 6/3/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 33,700 | $0 | 2/5/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 10,000 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,047 | $40K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,005 | $39K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,000 | $39K | 6/5/2023 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,500 | $85K | 5/31/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,500 | $98K | 5/31/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 7,900 | $0 | 6/8/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 5,000 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,106 | $68K | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.